Devika Ashok
Senior Scientist II, Translational Medicine AbbVie
Seminars
Thursday 29th January 2026
Informing Biomarkers for Multi-Specific Immune Cell Engagers Using Preclinical Models
5:15 pm
- T and NK cells mediate anti-tumor activity by multiple mechanisms in the tumor microenvironment and the current landscape to engage these cells includes check point inhibitors, immune cell engagers, and CAR cells
- ABBV-303 is a tumor targeting T and NK cell immune engager with potent cytotoxicity and immune cell modulation properties
- Immune cell activation, pro-inflammatory cytokine release, and cytotoxicity have been demonstrated with ABBV-303 using in-vivo and ex-vivo platforms
Thursday 29th January 2026
Fireside Chat: Optimizing Model Selection for Speed, Cost & Translatability to De-Risk Preclinical Development Under Resource Constraints
2:00 pm
- Navigating budget limitations and tight timelines while selecting models with strong translational potential to accelerate preclinical development without compromising predictive accuracy
- Prioritizing model complexity versus practical feasibility across organoids, PDX, and in silico platforms to maximize ROI and clinical relevance within resource-constrained environments
- Implementing tiered model selection strategies that balance throughput, cost effectiveness, and biological fidelity to de-risk candidates faster while maintaining translational confidence
